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Background: While the assessment of analytical precision within medical laboratories has received much attention
in scientific enquiry, the degree of as well as the sources causing variation between them remains incompletely
understood. In this study, we quantified the variance components when performing coagulation tests with identical
analytical platforms in different laboratories and computed intraclass correlations coefficients (ICC) for each
coagulation test.
Methods: Data from eight laboratories measuring fibrinogen twice in twenty healthy subjects with one out of 3
different platforms and single measurements of prothrombin time (PT), and coagulation factors II, V, VII, VIII, IX, X, XI
and XIII were analysed. By platform, the variance components of (i) the subjects, (ii) the laboratory and the
technician and (iii) the total variance were obtained for fibrinogen as well as (i) and (iii) for the remaining factors
using ANOVA.
Results: The variability for fibrinogen measurements within a laboratory ranged from 0.02 to 0.04, the variability
between laboratories ranged from 0.006 to 0.097. The ICC for fibrinogen ranged from 0.37 to 0.66 and from 0.19 to
0.80 for PT between the platforms. For the remaining factors the ICC’s ranged from 0.04 (FII) to 0.93 (FVIII).
Conclusions: Variance components that could be attributed to technicians or laboratory procedures were
substantial, led to disappointingly low intraclass correlation coefficients for several factors and were pronounced for
some of the platforms. Our findings call for sustained efforts to raise the level of standardization of structures and
procedures involved in the quantification of coagulation factors.
Keywords: Inter-rater variability, Intraclass correlation coefficient, Reproducibility of testing, Test validityIntroduction
While the assessment of analytical precision within one
medical laboratory has received much attention in scien-
tific enquiry, extent and sources of variability that occur
between laboratories quantifying the same parameter re-
mains incompletely understood. In view of the fact that
the clinical value of a laboratory test depends directly on
its reproducibility and comparability [1], the scientific
community has made great efforts to promote analytical* Correspondence: walter.wuillemin@luks.ch
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reproduction in any medium, provided the orprecision within laboratories lately [2-4]. For example,
external quality assessment programs (EQA) were intro-
duced to improve comparability between laboratories
and are seen as an essential part of quality management
systems today [3-5]. Nevertheless, data on variability be-
tween laboratories remain limited and analysis of variance
components are scarce. Available investigations indicate a
large variability, even in the context of coagulation param-
eter measurements [5-8] thus jeopardizing the compar-
ability of results between different institutions.
On the other hand, knowledge is also scarce for causal
sources of variability between laboratories. Possible in-
fluences may be the type of the parameter, reagents and
calibrators used, the level of standardisation within eachLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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gations could identify factors that contribute to the vari-
ability between laboratories, efforts could be made to
improve comparability efficiently. In this study, using
the example of haemostasis, we quantified the variance
components when performing coagulation tests with
identical analytical platforms in different laboratories
and computed intraclass correlations coefficients (ICC)
for each coagulation test. Thus, we aimed to quantify
the extend of variation between state-of-the-art labora-
tories in relation to the variation of the subjects and to
determine the sources of this variation.
Materials and methods
Study design and population
This investigation was a secondary analysis based on a
previous study of the Swiss RIVAMOS study group [10].
In this multicentre, prospective evaluation study blood
samples of 20 eligible and consenting healthy male vol-
unteers were included. The study was approved by the
local ethical review board of our institution (Kantonale
Ethikkommission Luzern).
Variance components of coagulation tests between
laboratories
Variability of coagulation tests between laboratories is
influenced by biological and analytical variability. The
two main components of biological variability are intra-
and inter-individual variability [11]. Analytical variability
between laboratories is influenced (a) by the variability
within laboratories, (b) by the platforms used, (c) the
assay designs used and (d) variance components that
could be attributable to technicians and laboratory pro-
cedures (including the choice of reagents and calibra-
tors). The type of coagulation factor measured may also
influence the variability. To investigate the variability be-
tween laboratories, we included the inter-individual vari-
ability, the variability within laboratories, the variability
between laboratories and the remaining variability (vari-
ance components, that could be attributable to techni-
cians and laboratory procedures) in our statistic model
as described below. The remaining factors are consid-
ered as stable due to several reasons. The intra-
individual variability is regarded as low in coagulation
tests and the interval between the two measurements is
very short (2–3 hours) [11]. Influence of the platform
was addressed as calculations have been done by every
platform. The assay designs were identical by platform.
Preanalytic factors were considered by applying a strict
protocol and using the same technician for serial mea-
surements. Storage and transport of the samples were
identical for all laboratories. To avoid influences of dif-
ferent batches of reagents, all determinations were done
in one batch in every laboratory.Blood withdrawal and handling of the samples
Citrated plasma samples were taken two times in an inter-
val of 2 to 3 hours at the senior author’s institution. Blood
withdrawal was done under standardised conditions to pre-
clude preanalytic influences. Plastic syringes (MonovetteW,
Sarstedt, Nümbrecht, Germany) containing 1 ml trisodium
citrate (0.106 mol/l) for 9 ml of blood were used. Citrated
samples were collected after EDTA samples to avoid tissue
factor contamination of citrated samples. Plasma samples
were snap-frozen at – 20°C and shipped under standar-
dised conditions using a commercial courier service with a
delivery time of 2–4 hours.
Laboratories and analysis
All nine haemostasiological laboratories of tertiary hospitals
in Switzerland participated in this investigation (In alpha-
betical order; Cantonal Hospital Aarau, University Hospital
of Basel, Inselspital University Hospital of Berne, University
Hospital of Geneva, University Hospital of Lausanne,
Regional Hospital of Locarno, Cantonal Hospital of
Lucerne, Cantonal Hospital of St. Gallen, University
Hospital of Zurich). One laboratory was excluded from
analysis of between-laboratory variability because of a
unique platform. The remaining eight laboratories used
one out of three platforms. Details of coagulometers,
assays and reagents used are given in Table 1. For deter-
mination of variability between laboratories, local pro-
tocols were used for testing samples. All laboratories
used strict internal and external quality assessment mea-
sures, conducted formal test evaluation and are accredited
to the Swiss Accreditation Service (SAS). Coagulation tests
have been done in accordance with international guide-
lines [12].
Fibrinogen was determined in plasma samples of both
points in time. Prothrombin time (PT), factors II, V, VII,
VIII, IX, X, XI and XIII were determined only for the
first sample to avoid possible interferences with the sec-
ond investigation conducted [10].
Statistical analysis
To study the variability between the different laborator-
ies, we performed analyses of variance (ANOVAs) and
used the variance components procedure. By platform,
the variance components of (i) the subjects, (ii) the la-
boratory and the technician (including the measurement
error of the platform) and (iii) the total variance were
obtained for fibrinogen as well as (i) and (iii) for the
remaining factors.
Based on the variance components, we calculated the
intraclass correlation coefficients (ICC) for all factors
using the variance component of the subjects in the nu-
merator and the total variance in the denominator.
Thus, the variation of the measurements between la-
boratories can be demonstrated in relation to the
Table 1 Participating laboratories with coagulometers, assays and reagents used
Laboratory¶ Platform Extrinsic coagulation factors‡ Intrinsic coagulation factors§ Fibrinogen Factor XIII
Assay Reagents Assay Reagents Assay Reagents Assay Reagents
A † Instrumentation Laboratory
ACL Top 700
Clotting test
(photometric)
Recombi-
plastinW
Clotting test
(photometric)
HemosilW
APPT SP
Clauss
method
HemosilW Fibrinogen-C Kinetic
photometric assay
BerichromW FXIII
B Siemens BCS-XP Clotting test
(photometric)
InnovinW Clotting test
(photometric)
ActinW Clauss
method
Multifibren U Kinetic
photometric assay
BerichromW FXIII
C Roche STA-R Clotting test
(viscosity)
InnovinW Clotting test
(viscosity)
Actin FSW Clauss
method
STAW Fibrinogen Latex
immunturbidimetry
HEXAMATEW FXIII
D Sysmex CA7000 Clotting test
(photometric)
InnovinW Clotting test
(photometric)
ActinW Clauss
method
DadeW Thrombin n.a. n.a.
E Siemens BCS-XP Clotting test
(photometric)
InnovinW Clotting test
(photometric)
PathromtinW
SL
Clauss
method
Multifibren U Kinetic
photometric assay
BerichromW FXIII
F Siemens BCS Clotting test
(photometric)
InnovinW Clotting test
(photometric)
Actin FSW Clauss
method
Multifibren U Kinetic
photometric assay
BerichromW FXIII
G* Sysmex CA1500 Clotting test
(photometric)
InnovinW Clotting test
(photometric)
Actin FSW Clauss
method
DadeW Thrombin n.a. n.a.
H Siemens BCS-XP Clotting test
(photometric)
InnovinW Clotting test
(photometric)
PathromtinW
SL
Clauss
method
Multifibren U Kinetic
photometric assay
BerichromW FXIII
I Roche STA-R Clotting test
(viscosity)
InnovinW Clotting test
(viscosity)
STAW APPT Clauss
method
bovine thrombin,
Diagnotec AG
Kinetic
photometric assay
BerichromW FXIII
¶ Random order, not matching with the alphabetical list mentioned above. * Laboratory was excluded from analysis of variability between laboratories because not all tests were available. † Laboratory was excluded
from analysis of variability between laboratories because of a unique platform. ‡ PT, Factors II, V, VII, X. § Factors VIII, IX, XI.
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Table 2 Intraclass correlations of various coagulation
tests and intraobserver variability of fibrinogen tests
with various platforms
Parameter Platform 1* Platform 2 Platform 3 Platform 4‡
# laboratories 1 2 4 2
Fibrinogen 0.85 0.37 0.65 0.66
Within-
laboratory
variability ¶
0.02 0.03 0.04
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ation). A high ICC (clearly above 0.5) refers to the sub-
jects as main components of the variance (which is a
desirable outcome) whereas a low ICC indicates that
other (non-subject) factors are more accountable (which
is a disturbing outcome).
Statistical analysis was performed using the SPSS statis-
tical software package (Version 19; Property of SPSS Inc
an IBM Company. © Copyright SPSS Inc. 1989, 2010).Between-
laboratory
variability +
0.097 0.03 0.006
Prothrombin
time
0.19 0.24 0.80
F II 0.44 0.04
F V 0.63 0.22
F VII 0.71 0.82
F VIII 0.93 0.61
F IX 0.86 0.83
F X 0.82 0.70
F XI 0.90 0.65
F XIII 0.57 0.81
* laboratory was excluded from analysis of between-laboratory variability
because of a unique platform, ‡ analysis was limited to routine coagulation
parameters, because one laboratory did not assess all tests, ¶ (Platform +
Technician), + Laboratories use the platform in different ways (they interpret
the manual differently).Results
A total of 360 fibrinogen measurements, 180 PT mea-
surements, 160 F II, F V, F VII, F VIII, F IX, F X and F
XI measurements, and 140 F XIII measurements were
available for analysis because only fibrinogen was deter-
mined two times and one laboratory did not provided all
tests. Raw data for all analysis are available at Additional
file 1: Table S1.
The intraobserver variability for fibrinogen measure-
ments, indicating the variability within a laboratory, ranged
from 0.02 to 0.04. This variability occurs from the variabil-
ity within a laboratory (including the technician handling
the samples). The variability between laboratories ranged
from 0.006 to 0.097. This indicates that laboratories used
the platform in different ways or that they interpreted the
manual differently. This detailed analysis was only possible
for the fibrinogen measurement because fibrinogen was
determined in plasma samples of both points in time.
The results allow discussing how prone a platform –
the specifications, the complexity in the handling and
other reasons – might be to create higher variability
when used in different laboratories and contexts.
The ICC for fibrinogen ranged from 0.37 to 0.66 and
from 0.19 to 0.80 for PT between the laboratories.
Though, the amount to which non-subject factors is ac-
countable for the variance of the parameters is very
varying. Low ICC indicates that non-subject factors are
major components of variance.
The ICC of FII when assessed with platform 3 was as
low as 0.04 as compared to 0.44 when measured with plat-
form 2. For the remaining factors the ICC’s ranged from
0.22 (F V) assessed with platform 3, to 0.93 (F VIII)
assessed with platform 2.
For the two platforms providing enough data, the aver-
age ICC across all parameters was 0.64 (standard devi-
ation 0.25) for platform 2 and 0.56 (standard deviation
0.28) for platform 3. Overall, the ICC’s were at 0.60 on
average. Details are available on Table 2.Discussions
Variance components that could be attributed to techni-
cians or laboratory procedures were substantial, led to
disappointingly low intraclass correlation coefficients forseveral factors and were pronounced for some of the
platforms, probably for those allowing more instrument
adjustments. Our results emphasise that variability of
parameters between state-of-the-art laboratories remains
considerable. This may have a relevant impact on the re-
producibility and comparability of the results.
Our results confirm and extend previous reports on a
wide variability of coagulation parameters. A wide vari-
ability of PT measurements was already noticed with the
introduction of early automation coagulometers [13]. An
investigation of the World Federation of Haemophilia
(WFH) EQA programme and the United Kingdom
National External Quality Assessment Scheme (UK
NEQAS) conducted in the UK and in emerging countries
revealed a good to acceptable variation with regard to PT
and aPTT (coefficient of variation [CV]: 10.1-20.4%) but
an extensive variation with regard to FVIII, FIX and von
Willebrand factor determination (CV 6-154%) [14]. Con-
siderable variations in determination of von Willebrand
factor antigen (vWF:Ag) and ristocetin cofactor activity
(vWF:RCo) were recognised in investigations of the U.S.
College of American Pathologists proficiency testing
(CV 3.2-30.9%; n = 171 laboratories) [14], the European
Concerted Action on Thrombosis and Disabilities Foun-
dation (CV 10-40%; n = 181 laboratories) [15] and UK
NEQAS (CV 15-50%; n = 200) [16].
Switzerland, February 1–4, 2012.
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supratherapeutic levels in the monitoring of unfractionated
heparin using activated partial thromboplastin time or
anti-Xa level was very limited in a cross-validation study
[17] as well as a study using the results of the annual
Ontario Quality Management Program [6]. An interlabo-
ratory agreement of 16-52% and a coefficient of variation
of 10.5 – 65% were reported respectively. Another investi-
gation used the results of the Italian External Quality
Assessment Scheme and found a wide variability in esti-
mation of quantitative D-Dimers (coefficient of variation
up to 47%) [18]. A high degree of variation between labo-
ratories in the identification of coagulation factor inhibi-
tors was shown in several investigations, which used data
of external quality assessment programs [7,19-21]. Other
investigations identified the type of the reagent [22], the
method of the assay [23] and the calibrator [24,25] as fac-
tors that bias the measurements between different labora-
tories and the coagulometer influencing the precision of
the measurements [22].
In contrast to these previous investigations, our study
illustrates the degree of variation between laboratories
using state-of-the-art coagulometers and reagents in rela-
tion to the variation of the subjects. We showed the de-
gree of variation for PT, fibrinogen and coagulation
factors II, V, VII, VIII, IX, XI and XIII. Furthermore, we
characterised factors associated with technicians and la-
boratory procedures as a relevant source of this variation.
These factors include also the choice of the reagents,
which may have influenced the higher between-laboratory
variability of platform 2 in contrast to platform 3.
Our investigation has several limitations. First, it is an
exploratory study with a relative low number of determi-
nations. However, it facilitates future investigations with
more determinations and a proper power analysis. Sec-
ond, “factors associated with technicians and laboratory
procedures” are determined as a global factor. The de-
sign of the study did not allow discriminating additional
potential factors such as type of the reagents, which are
also inadequately addressed by the literature.
Future investigations have to separate these factors to
discriminate between organisational factors and single
technicians. Third, only fibrinogen determination was
analysed for two points in time, because of the study de-
sign. If future investigations would determine more pa-
rameters two times, better information on differences
between parameters would be possible. Forth, only state-
of-the-art laboratories specialised in determination of
coagulation factors measured the samples in our investi-
gation. The results could possibly be different if routine
laboratories would have been investigated.
The strength of our study is that was done it in a nation-
wide design including only state-of-the-art coagulation la-
boratories of all tertiary hospitals. Therefore, a selectionbias appears unlikely. Furthermore, a wide range of coagu-
lation parameters was determined. Though, the observed
effects were internally confirmed by other parameters.
Moreover, it is one of the first investigations that observed
the sources of this variation and – to our knowledge – the
first investigation, which observed factors associated with
technicians and laboratory procedures as possible source
for variation of results between laboratories.
The present results suggest that variability of coagulation
parameters between specialised laboratories is substantial
despite state-of-the-art coagulometers and reagents, great
efforts to guarantee precision of laboratory tests and exter-
nal quality assessment programs. The results indicate that
factors associated with technicians and laboratory proce-
dures are a relevant source of this variation. Though, or-
ganisational factors are a promising field of work for future
investigations on the sources of this variability. Further-
more, efforts to enhance laboratory organisation may be an
attractive area of activity for reducing variability of the
measurements of coagulation parameters as well as im-
proving quality of laboratory results within laboratories.
This hypothesis is supported by the fact that platforms,
which allow more adjustments, were associated with a
greater variance than others with a more rigid application.
Furthermore, parameters, which necessitate a greater effort
in structuring operation procedure, have had a lower vari-
ance than more simple parameters.
In conclusion, variability between laboratories in deter-
mination of coagulation parameters was considerable
and variance components that could be attributable to
technicians and laboratory procedures were substantial.
Once confirmed in larger studies, our findings call for
sustained efforts to raise the level of standardization of
structures and procedures involved in the quantification
of coagulation factors.
Additional file
Additional file 1: Table S1. Raw data of coagulation tests obtained by
platform.
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